PMID- 10465105
OWN - NLM
STAT- MEDLINE
DCOM- 19991008
LR  - 20071115
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 5
IP  - 4
DP  - 1999
TI  - Long-term follow-up of patients who achieved complete remission after donor 
      leukocyte infusions.
PG  - 253-61
AB  - Donor leukocyte infusions (DLI) can induce a direct graft-vs-leukemia (GVL) 
      reaction and restore complete remission for patients who relapse after allogeneic 
      bone marrow transplantation (BMT). A critical and unanswered concern is the 
      long-term safety and durability of DLI. To determine remission duration, 
      long-term toxicity, and survival after DLI-induced remissions, we identified 73 
      patients who achieved complete remission after DLI. Follow-up information was 
      obtained for 66 of the 73 patients, including 39 patients with chronic 
      myelogenous leukemia (CML) and 27 patients with other diseases. Median follow-up 
      for all patients was 32 months; the probability of survival at 1, 2, and 3 years 
      was 83% (95% confidence interval [CI] 74-92), 71% (60-83), and 61% (49-74), 
      respectively. For CML, survival probability at 1, 2, and 3 years was 87% (76-98), 
      76% (62-90), and 73% (58-88). For other diseases, survival probability at 1 and 2 
      years is 77% (61-93) and 65% (46-84). Five of 39 patients with CML relapsed, and 
      11 of 27 patients with other diseases relapsed. Treatment-related toxicity 
      accounted for 10 deaths. Extended follow-up shows that DLI-induced remissions are 
      durable, especially for patients with CML. Late relapses still occur, however, 
      and toxicity remains significant. Continued follow-up will best define the 
      long-term GVL effects of DLI, especially for diseases other than CML.
FAU - Porter, D L
AU  - Porter DL
AD  - Department of Medicine, University of Pennsylvania Medical Center, Philadelphia 
      19104, USA.
FAU - Collins, R H Jr
AU  - Collins RH Jr
FAU - Shpilberg, O
AU  - Shpilberg O
FAU - Drobyski, W R
AU  - Drobyski WR
FAU - Connors, J M
AU  - Connors JM
FAU - Sproles, A
AU  - Sproles A
FAU - Antin, J H
AU  - Antin JH
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone Marrow Transplantation/adverse effects/mortality
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/etiology
MH  - Graft vs Tumor Effect
MH  - Humans
MH  - Leukemia/therapy
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/therapy
MH  - *Leukocyte Transfusion/adverse effects/mortality
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Safety
MH  - Survival Rate
MH  - Time Factors
MH  - Transplantation, Homologous/methods/mortality
EDAT- 1999/08/28 09:00
MHDA- 2001/03/28 10:01
CRDT- 1999/08/28 09:00
PHST- 1999/08/28 09:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1999/08/28 09:00 [entrez]
AID - S1083-8791(99)50015-3 [pii]
AID - 10.1053/bbmt.1999.v5.pm10465105 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 1999;5(4):253-61. doi: 
      10.1053/bbmt.1999.v5.pm10465105.